Intellia Therapeutics, Inc.
NTLANASDAQHealthcare● Active
$13.49
$-0.05(-0.37%)
Market Cap$1.5B
P/E Ratio—
52W High$28.25
52W Low$7.31
Intellia Therapeutics, Inc. (NTLA) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · NTLA · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $67.67M | $57.88M | $36.27M | $52.12M | $33.05M |
| Cost of Revenue | $15.92M | $10.29M | $8.98M | $7.57M | $6.89M |
| Gross Profit | $51.75M | $47.59M | $27.30M | $44.55M | $26.16M |
| Gross Margin %(computed) | 76.47% | 82.23% | 75.26% | 85.47% | 79.15% |
| Operating Expenses | |||||
| R&D Expenses | $388.86M | $466.31M | $435.07M | $419.98M | $229.81M |
| G&A Expenses | $119.80M | $125.83M | $116.50M | $90.31M | $71.10M |
| Total Operating Expenses | $492.74M | $581.86M | $542.59M | $502.71M | $294.01M |
| Operating Income | ($440.99M) | ($534.26M) | ($515.29M) | ($458.16M) | ($267.85M) |
| Operating Margin %(computed) | -651.67% | -923.10% | — | -879.04% | -810.37% |
| Interest Income | $29.20M | $47.81M | $49.83M | $8.54M | $1.28M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($412.69M) | ($519.02M) | ($481.19M) | ($474.19M) | ($267.89M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($412.69M) | ($519.02M) | ($481.19M) | ($474.19M) | ($267.89M) |
| Net Margin %(computed) | -609.85% | -896.77% | — | -909.78% | -810.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| Wtd Avg Shares | 108.38M | 98.85M | 88.77M | 76.97M | 70.89M |
| EBITDA | ($396.77M) | ($523.98M) | ($506.31M) | ($450.59M) | ($260.96M) |
| EBITDA Margin %(computed) | -586.32% | -905.33% | — | -864.51% | -789.52% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Intellia Therapeutics, Inc. data
About Intellia Therapeutics, Inc. (NTLA) Income Statement
Intellia Therapeutics, Inc. (NTLA) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, NTLA reported revenue of $0.07B, gross profit of $0.05B (gross margin 76.47%), and net income of ($0.41B) — a net profit margin of -609.85%.
Frequently asked questions
NTLA · 4 questionsIntellia Therapeutics, Inc. (NTLA) reported revenue of $0.07B for 2025, up 16.9% year-over-year.
NTLA revenueNTLA salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08